These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 23798862)

  • 21. Prognostic factors for primary superficial transitional cell carcinoma of the bladder: a retrospective cohort study.
    Yang TB; Zeng FH; Sun ZQ
    Chin Med J (Engl); 2006 Nov; 119(21):1821-8. PubMed ID: 17097038
    [TBL] [Abstract][Full Text] [Related]  

  • 22. CD10 Is Again Expressed at a Certain Stage during the Neoplastic Process of Bladder Transitional Cell Carcinomas.
    Jang TJ
    Cancer Res Treat; 2012 Dec; 44(4):262-6. PubMed ID: 23341790
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Urinary bladder cancer in yemen.
    Al-Samawi AS; Aulaqi SM
    Oman Med J; 2013 Sep; 28(5):337-40. PubMed ID: 24044060
    [TBL] [Abstract][Full Text] [Related]  

  • 24. CD10 expression in tumour and stromal cells of bladder carcinoma: an association with bilharziasis.
    Abdou AG
    APMIS; 2007 Nov; 115(11):1206-18. PubMed ID: 18092952
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Does HER2/neu expression provide prognostic information in patients with advanced urothelial carcinoma?
    Gandour-Edwards R; Lara PN; Folkins AK; LaSalle JM; Beckett L; Li Y; Meyers FJ; DeVere-White R
    Cancer; 2002 Sep; 95(5):1009-15. PubMed ID: 12209684
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Polyoma virus-associated cellular changes in the urine and bladder biopsy samples: a cytohistologic correlation.
    Herawi M; Parwani AV; Chan T; Ali SZ; Epstein JI
    Am J Surg Pathol; 2006 Mar; 30(3):345-50. PubMed ID: 16538054
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Comparative morphological characteristics and immunophenotype of urothelial carcinomas of the renal pelvis and bladder].
    Osmanov YI; Gaibov ZA; Kogan EA; Radenska-Lopovok SG; Tursunov KZ
    Arkh Patol; 2018; 80(5):23-32. PubMed ID: 30335057
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Expression of the human mismatch repair gene hMSH2: a potential marker for urothelial malignancy.
    Leach FS; Hsieh JT; Molberg K; Saboorian MH; McConnell JD; Sagalowsky AI
    Cancer; 2000 May; 88(10):2333-41. PubMed ID: 10820356
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Stage progression in Ta papillary urothelial tumors: relationship to grade, immunohistochemical expression of tumor markers, mitotic frequency and DNA ploidy.
    Holmäng S; Andius P; Hedelin H; Wester K; Busch C; Johansson SL
    J Urol; 2001 Apr; 165(4):1124-8; discussion 1128-30. PubMed ID: 11257652
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Overexpression of semaphorin 3A in patients with urothelial cancer.
    Vadasz Z; Rubinstein J; Bejar J; Sheffer H; Halachmi S
    Urol Oncol; 2018 Apr; 36(4):161.e1-161.e6. PubMed ID: 29288007
    [TBL] [Abstract][Full Text] [Related]  

  • 31. CD10 immunohistochemical staining in urothelial neoplasms.
    Murali R; Delprado W
    Am J Clin Pathol; 2005 Sep; 124(3):371-9. PubMed ID: 16191505
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Predictive value of combined immunohistochemical markers in patients with pT1 urothelial carcinoma at radical cystectomy.
    Shariat SF; Bolenz C; Godoy G; Fradet Y; Ashfaq R; Karakiewicz PI; Isbarn H; Jeldres C; Rigaud J; Sagalowsky AI; Lotan Y
    J Urol; 2009 Jul; 182(1):78-84; discussion 84. PubMed ID: 19447418
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Reduced immunohistochemical PTEN staining is associated with higher progression rate and recurrence episodes in non-invasive low-grade papillary urothelial carcinoma of the bladder.
    Kulac I; Arslankoz S; Netto GJ; Ertoy Baydar D
    Virchows Arch; 2018 Jun; 472(6):969-974. PubMed ID: 29368083
    [TBL] [Abstract][Full Text] [Related]  

  • 34. p53 expression compared with other prognostic factors in OMS grade-I stage-Ta transitional cell carcinoma of the bladder.
    Casetta G; Gontero P; Russo R; Pacchioni D; Tizzani A
    Eur Urol; 1997; 32(2):229-36. PubMed ID: 9286659
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinical Use of Tumor Markers for the Detection and Prognosis of Bladder Carcinoma: A Comparison of CD44, Cytokeratin 20 and Survivin.
    Yikilmaz TN; Dirim A; Ayva ES; Ozdemir H; Ozkardes H
    Urol J; 2016 Jun; 13(3):2677-83. PubMed ID: 27351322
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Fascin is a predictor for invasiveness and recurrence of urothelial carcinoma of bladder.
    Bi J; Chen X; Zhang Y; Li B; Sun J; Shen H; Kong C
    Urol Oncol; 2012 Sep; 30(5):688-94. PubMed ID: 20888270
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prospective comparison of molecular signatures in urothelial cancer of the bladder and the upper urinary tract--is there evidence for discordant biology?
    Krabbe LM; Lotan Y; Bagrodia A; Gayed BA; Darwish OM; Youssef RF; Bolenz C; Sagalowsky AI; Raj GV; Shariat SF; Kapur P; Margulis V
    J Urol; 2014 Apr; 191(4):926-31. PubMed ID: 24060642
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Micropapillary variant of urothelial carcinoma of the urinary bladder; a clinicopathological and immunohistochemical study.
    Samaratunga H; Khoo K
    Histopathology; 2004 Jul; 45(1):55-64. PubMed ID: 15228444
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Human DNA topoisomerase-IIalpha expression as a prognostic factor for transitional cell carcinoma of the urinary bladder.
    Koren R; Kugel V; Dekel Y; Weissman Y; Livne PM; Gal R
    BJU Int; 2003 Apr; 91(6):489-92. PubMed ID: 12656900
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Tumorous CD10 Is More Strongly Related to the Progression of Urothelial Carcinoma than Stromal CD10.
    Kumagai-Togashi A; Uozaki H; Kikuchi Y; Watabe S; Numakura S; Watanabe M
    Anticancer Res; 2019 Feb; 39(2):635-640. PubMed ID: 30711939
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.